KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Liabilities (2019 - 2025)

Historic Total Liabilities for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $9.7 billion.

  • Royalty Pharma's Total Liabilities rose 2495.76% to $9.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 billion, marking a year-over-year increase of 2495.76%. This contributed to the annual value of $7.9 billion for FY2024, which is 2513.33% up from last year.
  • Per Royalty Pharma's latest filing, its Total Liabilities stood at $9.7 billion for Q3 2025, which was up 2495.76% from $8.8 billion recorded in Q2 2025.
  • Royalty Pharma's Total Liabilities' 5-year high stood at $9.7 billion during Q3 2025, with a 5-year trough of $6.1 billion in Q1 2021.
  • Over the past 5 years, Royalty Pharma's median Total Liabilities value was $7.3 billion (recorded in 2022), while the average stood at $7.3 billion.
  • Per our database at Business Quant, Royalty Pharma's Total Liabilities skyrocketed by 18484.32% in 2021 and then tumbled by 1359.11% in 2023.
  • Over the past 5 years, Royalty Pharma's Total Liabilities (Quarter) stood at $7.3 billion in 2021, then rose by 0.29% to $7.3 billion in 2022, then fell by 13.59% to $6.3 billion in 2023, then rose by 25.13% to $7.9 billion in 2024, then rose by 23.43% to $9.7 billion in 2025.
  • Its last three reported values are $9.7 billion in Q3 2025, $8.8 billion for Q2 2025, and $7.8 billion during Q1 2025.